Alexandria Real Estate Equities (ARE) has recently been the subject of various fluctuations and developments. It has seen a recent decrease in share prices, with significant underperformance in comparison to competitors. Resultantly,
JP Morgan and BMO Capital have respectively reduced the price target and lowered its rating. However, despite facing these tough times, it got recognized as one of
America's most charitable companies by Newsweek. Notably, the company has adjusted its balance sheet and dividend as shares rebound, and it's been dropped from the
FTSE All-World Index. The shares of ARE got
acquired by Davis Selected Advisers and sold by Swiss National Bank.
BMO Capital downgraded ARE to hold rating, citing a decline in share price. Amid these challenges, the company has forged a strategic partnership with Lilly on a new project to accelerate the development of life-changing medicines. ARE continues to face legal troubles and marked a significant dip after a dividend cut. Despite these challenges, ARE's valuation after a sharp share price decline must be reassessed, suggesting a possible investment opportunity.
Alexandria Real Estate Equities ARE News Analytics from Mon, 14 Jul 2025 07:00:00 GMT to Sat, 28 Mar 2026 06:05:00 GMT -
Rating -2
- Innovation 0
- Information 7
- Rumor -6
